share_log

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Benzinga ·  Nov 27 20:28  · Ratings

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment